相似文献
1
Matrix Regenerating Agent (RGTA) in a Neurotrophic Corneal Ulcer.
Cureus. 2020 Oct 26;12(10):e11167. doi: 10.7759/cureus.11167.
2
Healing of resistant corneal neurotrophic ulcers using a matrix regenerating agent.
J Fr Ophtalmol. 2019 Feb;42(2):159-165. doi: 10.1016/j.jfo.2018.05.009. Epub 2018 Dec 17.
3
Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8181-5. doi: 10.1167/iovs.12-10476.
4
Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent.
J Ocul Pharmacol Ther. 2017 Nov;33(9):662-669. doi: 10.1089/jop.2017.0010. Epub 2017 Sep 14.
5
[Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].
J Fr Ophtalmol. 2008 May;31(5):465-71. doi: 10.1016/s0181-5512(08)72462-8.
6
Matrix Regeneration Therapy: A Case Series of Corneal Neurotrophic Ulcers.
Cornea. 2016 Apr;35(4):451-5. doi: 10.1097/ICO.0000000000000759.
7
Investigation of topical amniotic membrane suspension and ReGeneraTing Agent on early corneal stromal healing in rats.
Vet Anim Sci. 2024 Mar 7;24:100344. doi: 10.1016/j.vas.2024.100344. eCollection 2024 Jun.
8
Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers.
Expert Opin Investig Drugs. 2019 Nov;28(11):1013-1020. doi: 10.1080/13543784.2019.1677605. Epub 2019 Oct 15.
9
The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACICOL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage.
Histol Histopathol. 2014 Apr;29(4):457-78. doi: 10.14670/HH-29.10.457. Epub 2013 Oct 9.
10
Management of corneal neurotrophic ulcers with Cacicol®-RGTA (ReGeneraTing Agent): a case series.
Arch Soc Esp Oftalmol (Engl Ed). 2020 Sep;95(9):421-428. doi: 10.1016/j.oftal.2020.04.015. Epub 2020 Jun 17.
引用本文的文献
1
Control of tissue homeostasis by the extracellular matrix: Synthetic heparan sulfate as a promising therapeutic for periodontal health and bone regeneration.
Periodontol 2000. 2024 Feb;94(1):510-531. doi: 10.1111/prd.12515. Epub 2023 Aug 24.
本文引用的文献
1
Evaluation of corneal epithelial wound healing after penetrating keratoplasty in patients receiving a new matrix therapy agent (regenerating agent).
Eur J Ophthalmol. 2020 Jan;30(1):119-124. doi: 10.1177/1120672118808971. Epub 2018 Oct 31.
2
Neurotrophic Keratopathy: Therapeutic Approach Using a Novel Matrix Regenerating Agent.
J Ocul Pharmacol Ther. 2017 Nov;33(9):662-669. doi: 10.1089/jop.2017.0010. Epub 2017 Sep 14.
3
Effect of a New Matrix Therapy Agent in Persistent Epithelial Defects After Bacterial Keratitis Treated With Topical Fortified Antibiotics.
Cornea. 2017 Sep;36(9):1061-1068. doi: 10.1097/ICO.0000000000001261.
4
RGTA or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients.
Glycoconj J. 2017 Jun;34(3):325-338. doi: 10.1007/s10719-016-9744-5. Epub 2016 Dec 7.
5
Diagnosis and management of neurotrophic keratitis.
Clin Ophthalmol. 2014 Mar 19;8:571-9. doi: 10.2147/OPTH.S45921. eCollection 2014.
6
RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies.
J Fr Ophtalmol. 2013 Nov;36(9):740-7. doi: 10.1016/j.jfo.2013.01.012. Epub 2013 Aug 16.
7
Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.
Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8181-5. doi: 10.1167/iovs.12-10476.
8
[First applications of matrix therapy in plastic and aesthetic surgery].
Ann Chir Plast Esthet. 2010 Oct;55(5):421-8. doi: 10.1016/j.anplas.2010.07.011. Epub 2010 Sep 24.
9
[Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment-resistant corneal ulcers and corneal dystrophy].
J Fr Ophtalmol. 2008 May;31(5):465-71. doi: 10.1016/s0181-5512(08)72462-8.
Zotero 插件
